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Objective: To validate a clinical database for nonmelanoma skin cancer (NMSC) with the aim 
of monitoring and predicting the prognosis of NMSC treated by dermatologists in clinics in the 
central and north Denmark regions.
Methods: We assessed the completeness of registration of patients and follow-up visits, 
and positive predictive value (PPV), negative predictive value (NPV), sensitivity, and 
specificity of registrations in the database. We used the Danish Pathology Registry (DPR) 
(n = 288) and a review of randomly selected medical records (n = 67) from two clinics as 
gold standards.
Results: The completeness of registration of patients was 62% and 76% with DPR and medical 
record review as gold standards, respectively. The completeness of registration of 1st and 2nd 
follow up visits was 85% and 69%, respectively. The PPV and NPV ranged from 85% to 99%, 
and the sensitivity and specificity from 67% to 100%.
Conclusion: Overall, the accuracy of variables registered in the NMSC database was satis-
factory but completeness of patient registration and follow-up visits were modest. The NMSC 
database is a potentially valuable tool for monitoring and facilitating improvement of NMSC 
treatment in dermatology clinics. However, there is still room for improvement of registration 
of both patients and their follow-up visits.
Keywords: nonmelanoma skin cancer, validation, database, positive predictive value, 
completeness
Introduction
Nonmelanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC), is the most common malignancy in western 
countries.1,2 The annual incidence of NMSC is rapidly increasing and NMSC has 
therefore become a significant challenge in terms of public health management and 
health care costs.3–5 However, high quality epidemiological data on NMSC is sparse 
due to incomplete registration of NMSC in cancer registries.4 While the Danish 
  Cancer Registry (DCR), for example, contains basic information on incident cases, 
the   completeness of BCC lesion registration is only 50%.1
Detailed data on NMSC and the treatment of NMSC in everyday clinical practice 
are important for surveillance, prediction of prognosis, improvements in quality of 
care and treatment, and for research purposes.4,6 Such data can be obtained from prop-
erly designed clinical databases, which are an attractive source for epidemiological 
research.6,7 However, the very high incidence of NMSC, as well as the common de 
novo occurrences of skin cancers seen among NMSC patients, poses a challenge to 
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NMSC data collection. A result of this may be the incomplete 
registration of NMSC in population-based cancer registries 
throughout the world.2,8
In Denmark, most NMSCs are treated by dermatologists 
in dermatology clinics free of charge. Approximately two-
thirds of all specimens registered in the Danish Pathology 
Registry (DPR) with a diagnosis of either BCC or SCC origi-
nate from patients diagnosed and treated by dermatologists.9 
A Danish regional clinical database of NMSC diagnosed and 
treated by dermatologists was established in 2007. The data-
base aims to examine the epidemiology of NMSC, Bowen’s 
disease, and keratoacanthoma treated by dermatologists in 
private clinics, and to examine the epidemiology of treatment 
procedures. The database will also be used to monitor the 
treatment effect and to facilitate improvement in the outcome 
of NMSC treatment in everyday clinical practice by providing 
data on predictors for disease outcome.
Validation of data is crucial to assess the usefulness of 
a clinical database as a valuable tool for answering clinical, 
administrative, and research questions.10 Thus, the aim of 
this study was to validate the data quality and completeness 
of NMSC cases in the Danish regional NMSC dermatology 
database.
Material and methods
The Danish Regional NMSC  
Dermatology Database
‘The Danish Regional NMSC Dermatology Database’ (The 
NMSC database) was initiated in cooperation with the   Danish 
Dermatological Society in 2007. An online registration sys-
tem was developed and registration in the database began as 
a pilot study in July 2007. In the pilot phase, two dermatol-
ogy clinics in the Central Denmark Region (each with two 
full-time dermatologists) registered consecutive patients in 
the database. In August 2008, 15 of 19 private clinics in the 
two regions accepted affiliation with the database, and since 
October 2008, 10 of the clinics have registered data in the 
database.
In April 2009, the Danish National Board of Health 
approved the database as a regional clinical database. Since 
then, it has been mandatory for dermatologists in private clin-
ics in the Central Denmark Region, and for certain clinics in 
the North Denmark Region, to register data in the database. 
By December 2009, only four of the 19 eligible clinics were 
still not affiliated with the database.
The database contains detailed information on type of 
NMSC, treatment, and prognosis after treatment in the private 
dermatology clinics. On the day of treatment, the   treating 
dermatologist completes a questionnaire with detailed 
  information on the tumor and patient-related factors, as well 
as performed treatments (Appendix 1). It is also mandatory 
for dermatologists to register NMSC cases in the DCR. To 
minimize the burden of registration, data from the NMSC 
database registration system can be transferred directly to 
the DCR on completion of the questionnaire. This procedure 
aims to avoid missing data in the NMSC database.
NMSC patients are scheduled for two follow-up visits, 
one at three months (0–6 months) and one at 12 months 
(6–15 months) after treatment. At these visits, information on 
recurrence, cosmetic result and complications are registered 
(Appendix 2).
Study population
In this validation study we included patients registered in 
the NMSC database from January 1 until June 30, 2008 
(288 patients with 359 lesions). The period was chosen to 
obtain a follow-up period of a minimum of 15 months for 
all tumors registered. In the study period, two dermatology 
clinics registered data in the database; in each clinic, two 
to three dermatologists entered data daily. To calculate the 
completeness of registration of patients with one or more 
histologically verified tumor(s), the study population was 
restricted to patients with lesions verified histologically.
In order to include tumors which were not verified histo-
logically, completeness of all tumor registration was assessed 
by reviewing medical records in the two clinics. Within the 
study period, three days from each of the six months were 
randomly selected for each clinic (a total of 36 working days). 
All contacts to the clinics on those days were reviewed via 
medical records in order to cover all contacts with patients 
with NMSC, Bowen’s diseases or keratoacanthoma. A total 
of 88 patients with 104 tumors were identified in the medical 
record review. Sixty-seven of the 88 patients from the medi-
cal record review were also registered in the NMSC database. 
This study population was used to calculate the completeness 
of the database and positive predictive values. When calcu-
lating completeness of registration of follow-up visits in the 
database, we excluded 13 of the 67 patients, since it is not 
mandatory for dermatologists to register follow-up visits for 
patients referred to hospital treatment, nor for patients with 
Bowen’s diseases or keratoacanthoma lesions.
Other data sources
The DPR contains information on histological examina-
tions performed in Denmark. Since 2005, reporting to the 
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employed pathologists. The registry includes information 
on referring department, the performing department, the 
date of the pathology test, and the associated histological 
diagnoses. All diagnoses are coded according to Systematized 
Nomenclature of Medicine (SNOMED).11 Patients registered 
with a SNOMED code of NMSC, Bowen’s disease, and 
keratoacanthoma in the DPR during the study period, were 
identified in the DPR. (See Appendix 3 for the full list of 
SNOMED codes).
The Danish Civil Registration System (CRS) contains 
information on all Danish residents who are assigned a unique 
10-digit personal civil registration number (CPR number) 
at birth or when immigrating into Denmark. Information 
on changes in vital status, such as emigration and death, 
is registered in CRS, and the unique CPR-number can be 
used to link information from different Danish registries.12 
The CRS was used to obtain information on vital status for 
patients in the study population.
Table 1 Descriptions of patients and tumors in the nonmelanoma skin cancer database
Registration from Jan 1 
2008 – Aug 31 2009 in the 
NMSC database (%)
Study population for 
calculation of completeness: 
Registration from 
Jan 1 – Jun 30 2008 (%)
Medical record reviews 
used to calculate PPV 
and completeness (%)
Total numbers of patients 1,775  288 67
  Male 892 (50) 136 (47) 31 (46)
  Female 883 (50) 152 (53) 36 (54)
Clinics
  Clinic no 1 457  178 (62) 39 (58)
  Clinic no 2 296  110 (38) 28 (42)
  Age , 55 264 (15) 49 (17) 16 (24)
  Age $ 55 and ,75 889 (50) 154 (53) 29 (43)
  Age $ 75 622 (35) 85 (30) 22 (33)
History of previous skin cancer
  No history of skin cancer 992 (56) 156 (54) 32 (48)
  History of previous skin cancer  737 (42) 130 (45) 34 (51)
  Unknown 45 (3) 2 (1) 1 (2)
  Missing 1 (–) 0  0
Total numbers of tumors 2,400 359 78
Histological diagnosis
  Basal cell carcinoma 2,090 (87) 328 (91) 72 (92)
  Squamous cell carcinoma 123 (5) 10 (3) 2 (3)
  Mb. Bowen 77 (3) 9 (3) 2 (3)
  Keratoacanthoma 34 (1) 7 (2) 2 (3)
  Keratoacanthoma/SCC 1 (–) 1 (–) 0
  No pathology test performed 57 (2) 4 (1) 0
  Histology inconclusive  10 (–) 0 0
  Missing histology registration 8 (–) 0 0
Tumor registered is
  A new primary tumor 2,173(91) 324 (90) 69 (88)
  A previously treated tumor 221 (9) 35 (10) 9 (12)
  Missing 6 (–) – –
Treatment modality
  Curettage with or without cautery 1,919 (80) 294 (82) 65 (83)
  Cryotherapy 38 (2) 3 (1) 0
  Excision 157 (7) 9 (3) 1 (1)
    Tangential excision with or 
without curettage
4 (–) 1 (–) 0
  Photodynamic therapy  55 (2) 15 (4) 1 (1)
  Imiquimod 42 (2) 1 (1)
  Referred to hospital treatment 152 (6) 28 (8) 9 (11)
  No treatment 17 (–) 1 (–) 0
  Treatment variable missing 16 (1) 6 (2) 1 (1)
Abbreviations: PPV, positive predictive value; SCC, squamous cell carcinoma. Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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Table 2 Completeness of registration of patients in the nonmelanoma skin cancer database
Patients  
registered  
in database  
(no.) 
Patients  
registered  
in the DPR
(no.)
Degree of  
completeness  
(Evaluation: DPR)  
% (95% CI)
Patients  
registered in  
database (no.)
Patients  
registered in the  
medical records 
(no.)
Degree of 
completeness 
(Evaluation:  
medical records) 
% (95% CI)
Overall patients 288 452 62 (58–67) 67 88 76 (66–85)
Completeness for each 
clinic
  Patients clinic no 1 178 182a 93 (88–94) 39 41 95 (84–99)
  Patients clinic no 2 110 270b 40 (34–46) 28 47 60 (44–74)
Abbreviations: CI, confidence interval; DPR, Danish Pathology Registry.
Medical records were reviewed from the two pilot 
  dermatology clinics and included in the validation study. 
The medical records were systematically reviewed and 
information retrieved on history of skin cancer, size, loca-
tion, treatment type, date of treatment, recurrences, cosmetic 
result, and complications related to treatment. Data were 
typed into EpiData 3.1 (The EpiData Association, Odense, 
Denmark).
Statistical analyses
Completeness of registration  
in the NMSC database
The completeness of registration of patients with a histologi-
cally verified tumor was assessed using the DPR as a gold 
standard. The completeness of registration was defined as the 
numbers of patients diagnosed with a tumor and registered 
in both the NMSC database and in the DPR, divided by the 
number of patients with the same diagnosis registered in 
the DPR.
To validate data on tumors which were not verified his-
tologically, completeness of registration of all tumors was 
defined as the number of patients with a clinically diagnosed 
tumor registered in the NMSC database and in the medical 
record, divided by the number of patients recorded in the 
medical record with either type of diagnosis; any histologi-
cally verified diagnosis overruled a clinical diagnosis.
Completeness of registration of 1st follow-up visits was 
defined as the number of patients registered with at least 
one follow-up visit in the database between 0–6 months 
after initial treatment, divided by the number of patients 
registered with a follow-up visit in the medical records. The 
  completeness of registration of a 2nd follow-up visit was 
defined as the number of patients registered with at least one 
follow-up visit in the NMSC database 6 to 15 months after 
initial treatment, divided by the number of patients registered 
with a follow-up visit in the medical records.
Accuracy
We evaluated the accuracy of the registrations in the NMSC-
database using the information obtained in the medical record 
review as a gold standard. However, for the variable ‘histo-
logical diagnosis’ we used the DPR as the gold standard, as 
the DPR contains the pathologist’s registration of the his-
tological diagnosis. For each of the registered variables, we 
estimated sensitivity, specificity, and positive and negative 
predictive values (PPV and NPV) where appropriate.13 We 
only included tumors registered in both the NMSC database 
and in the medical record. Please see Table 4 for detailed 
information on the calculation.
Where the information registered in the NMSC database 
disagreed with that in the medical record, the medical record 
was reviewed again and any uncertainty was discussed and 
clarified with an independent dermatologist.
Tumor size was considered in agreement if there was no 
more than 2 mm difference between the sizes registered in 
the database and in the medical record. In the database, tumor 
localization was registered by marking the tumor on a draw-
ing of the body. If this agreed with the written description 
of localization found in the medical record, the two were 
considered identical. Where the medical record had no 
information on complications, this was interpreted as ‘no 
complications’. In the NMSC database complications are 
recorded with a ‘yes’ or ‘no’.
Results
Table 1 lists characteristics of all registrations in the database 
until August 31 2009, characteristics of the study population 
(n = 288 patients), and characteristics of the patients regis-
tered in the database whose medical records were reviewed 
(n = 67 patients). Information on cosmetic results was not 
routinely recorded in the medical record and therefore was not 
retrieved. The study population and the sample selected for 
medical record review are representative of all   registrations  Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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in the database. Furthermore, the database had very little 
missing data.
Completeness
The overall completeness of registration of patients in the 
database was 62% when using the DPR as a gold standard 
(Table 2), but differed according to clinic. The   completeness 
in clinic 1 was 93%, whereas the completeness in clinic 2 
was 40%. Based on the medical record review, the com-
pleteness of registration of patients in the database was 
76% overall: 95% and 60% in clinic 1 and 2, respectively 
(Table 2).
Among the 54 patients eligible for registration of a 
  follow-up visit, 39 were registered with a 1st follow-up visit 
and 22 were registered with a 2nd follow-up visit in the 
NMSC database, and a total of 45 of the 54 patients were 
registered with either 1st or 2nd follow-up visit. Overall, 
the completeness of registration of 1st follow-up visits in 
the NMSC database compared with registration in the medical 
record review was 85%, but varied according to clinic: 100% 
and 71% in clinic 1 and 2, respectively. The completeness of 
registration of 2nd follow-up visits was 69% overall: 74% 
and 63% in clinic 1 and 2, respectively. The medical record 
review revealed that 18 of the 54 patients did not participate 
in a 2nd follow-up visit. Based on the medical record review 
and data from the CRS there were a number of reasons for 
nonparticipation in follow-up visits. Four patients had a 2nd 
follow-up later than 15 months after treatment; two patients 
had a recurrence at 1st follow-up and were referred to hospital 
for treatment; one patient died during follow-up; one patient 
had a tumor clinically assessed to be a keratoacanthoma; 
3 patients cancelled or failed to attend; while information 
on seven patients was missing (Table 3).
Accuracy of the registered variables
PPV , NPV , sensitivity, and specificity, are given in Tables 5 
and 6. The PPV , NPV , sensitivity, and specificity of his-
tologically verified diagnoses was 100%, using the DPR 
as a gold standard (Table 5). The PPV , NPV , sensitivity, 
and specificity of registration of a patient with first skin 
cancer were 97%, 94%, 97%, and 94%, respectively. The 
PPV , NPV , sensitivity, and specificity of tumor history (ie, 
a new primary tumor) were 99%, 100%, 100% and 90%, 
respectively. The PPV was 96% for localization, 85% for 
size, and the PPV of the date of treatment was 91%. The 
PPV of treatment modality registered was 95%. PPV, NPV, 
sensitivity, and specificity were calculated for the differ-
ent types of treatment ranging from 50%–100% (Table 6). 
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Table 4 Formulae to calculate the PPV, NPV, and sensitivity and specificity
NMSC database Medical record review
yes no
eg, First skin cancer ever Yes a b PPV = a/(a + b)
No c d NPV = c/(c + d)
Sensitivity = a/(a + c) Specificity = b/(b + d)
Notes: PPV, positive predictive value. The proportion of patients registered with ‘yes’ for a given variable in the database confirmed in the medical record (ie, the variable: 
diagnosis, according to the DPR) for variables: ‘diagnosis overall’, ‘treatment overall’, ‘size’, localization’ and ‘treatment date’ PPVs were the  proportion of a given variable 
registered in the database confirmed in the medical record/DPR; NMSC, nonmelanoma skin cancer; NPV, The proportion of patients registered with ‘no’ for a given variable 
in the database confirmed in the medical record (ie, the variable; diagnosis, according to the DPR); Sensitivity, The proportion of patients registered with ‘yes’ for a given 
variable in the medical record, who were registered with a ‘yes’ in the database (ie, the variable diagnosis, according to the DPR); Specificity, The proportion of patients with 
‘no’ for a given variable in the medical record, who were registered with a ‘no’ in the database (ie, the variable diagnosis, according to the DPR).
Abbreviations: DPR, Danish Pathology Registry; NMSC, nonmelanoma skin cancer; NPV, negative predicted value; PPV, positive predicture value.
Table 5 Validity of variables registered in the nonmelanoma skin cancer database. Verified in medical records
NMSC 
database
Medical record Total PPV 
% (95% CI)
NPV 
% (95% CI)
Sensitivity 
% (95% CI)
Specificity 
% (95% CI) yes no
Histological diagnosis  
overall
Total 78* 0 78 78/78 = 100 
(95–100)
  Basal cell carcinoma Yes 72 0 72 72/72 = 100 
(95.0–100)
6/6 = 100 
(54–100)
72/72 = 100 
(95–100)
6/6 = 100 
(54–100)
    Squamous cell  
carcinoma
Yes 2 0 2 2/2 = 100 
(15.8–100)
76/76 = 100 
(95–100)
2/2 = 100 
(15.8–100)
76/76 = 100 
(95–100)
  Mb. Bowen Yes 2 0 2 2/2 = 100 
(15.8–100)
76/76 = 100 
(95–100)
2/2 = 100 
(15.8–100)
76/76 = 100 
(95–100)
  Keratoacanthoma  Yes 2 0 2 2/2 = 100 
(15.8–100)
76/76 = 100 
(95–100)
2/2 = 100 
(15.8–100)
76/76 = 100 
(95–100)
Notes: Histological diagnosis confirmed in the medical record.
Abbreviations: CI, confidence interval; PPV, positive predictive value. NPV, negative predictive value.
nosis, localization, size, skin cancer history, and treatment). 
We had a low degree of missing data on these variables in the 
database, due to its electronic validation of the questionnaire 
before transfer of information to the DCR. Thus, registrations 
of prognostic and treatment related variables in the database 
are of high accuracy.10,14 PPV , NPV , sensitivity, and specific-
ity of the outcome variables (recurrence and complication) 
ranged from 67%–100%. However, our estimates were 
imprecise, due to small numbers of outcomes.
The completeness of patient registration in the NMSC 
database was high in clinic 1 and low in clinic 2, illustrating 
the challenge of registering data in everyday clinical practice. 
NMSC is a very common cancer. Complete registration of this 
cancer is vulnerable to, for example, physician time   pressure 
and manpower devoted to data registration in the NMSC 
database. Due to the modest overall completeness, the NMSC 
database cannot yet be used to calculate the true incidence of 
NMSC among patients treated in dermatology clinics.
The modest completeness of registration of 2nd follow-up 
visits in both clinics caused missing information on NMSC 
recurrences among patients registered in the database. 
PPV, NPV, sensitivity, and specificity of complications in 
  relation to treatment was 100%, 98%, 67%, and 100%. PPV , 
NPV, sensitivity, and specificity of recurrences registered 
at either 1st or 2nd follow-up was 100%, 98%, 75%, and 
100%. However, the number of recurrences was low and the 
medical record review revealed an incomplete registration 
of recurrences mainly due to the incomplete registration of 
follow-up visits. At 1st follow-up visits, two recurrences 
were registered in the NMSC database. The medical record 
review revealed one additional recurrence which had been 
mistakenly registered as no recurrence. At 2nd follow-up 
visit, one recurrence was registered. The medical record 
review revealed four additional recurrences which had not 
been registered due to incomplete registration of follow-up 
visits, and the sensitivity of registration of   recurrence 
(including the missing registration of follow-up visits) was 
then 38% (3/8).
Discussion
Our study showed a high PPV , NPV , sensitivity, and specific-
ity for the prognostic and treatment related variables (diag- Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Clinic 1 had the highest completeness resulting in the low-
est number of missing data. Missing data caused inaccuracy 
of the registration of complications and recurrences at 2nd 
follow-up visits. Inaccuracy of registration of outcome 
related variables is also seen in other databases.15–17 Hence 
in the future, measures will be taken to obtain higher com-
pleteness of registration. Clinics reporting to the database 
will therefore receive lists every third month on missing 
registration compared to DPR, as well as a list of missing 
registration of follow-up visits. This has shown to be effective 
in other databases.17,18 Additionally we will also regularly 
contact each clinic by phone in order to solve any registra-
tion problems and to act as a reminder to register patients 
in the database.
Strengths of this validation study include the extensive 
review of medical records with very detailed data on prognos-
tic factors, treatment, and outcome. This enabled validation of 
a high number of variables in the NMSC database. The risk 
of information bias was low since medical records were sys-
tematically reviewed using a standard form. Nonetheless, our 
study had some limitations including a lack of information on 
cosmetic results in medical records, as well as an incomplete 
registration of tumor sizes in the medical records. The low 
number of recurrences and complications registered in the 
NMSC database also caused imprecise estimates of the PPV . 
Another limitation is the lack of randomization of the two 
clinics included in the validation study. However, the clinics 
were chosen in order to obtain 15 months of follow-up, and 
patients treated at these clinics appear to be representative 
of all patients in the database.
The completeness of the NMSC database must be 
evaluated compared with available NMSC data sources. 
In Denmark, data on NMSC diagnoses is collected by the 
DCR. However, only basic information on incident cases is 
collected, and the completeness of incident BCC cases is 
estimated at only 50%.1 Data on NMSC is not routinely col-
lected in the major cancer databases.19,20 High quality data 
on NMSC is therefore sparse.
The NMSC database is unique compared with other data 
sources because of its detailed data on prognostic factors, treat-
ment, and outcome. We have shown that PPV , NPV , sensitivity, 
and specificity of prognostic and treatment related variables 
(diagnosis, localization, size, skin cancer history, and treatment) 
was high. Due to low numbers of outcome (recurrence and com-
plications) risk estimates were imprecise, and further examina-
tion of accuracy of the outcome variables is desirable.
Even though completeness is still not satisfactory, 
the high values of PPV, NPV, sensitivity, and specificity 
ensure high quality of data registered. In future, there-
fore, the database can be used to monitor treatment and to 
facilitate improvements in treatment of NMSC in everyday 
clinical practice by providing detailed data on predic-
tors for disease outcome, treatment, and treatment out 
come.
In conclusion, this validation study shows that the NMSC 
database has the potential to become a significant resource 
for epidemiological research of NMSC, and for monitor-
ing and facilitating improvement of treatments of NMSC, 
Bowen’s disease, and keratoacanthoma in dermatology 
clinics. However, there is still room for improvement of 
registration of both patients and their follow-up visits which 
will be a future aim.
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Appendix 1: Treatment questionnaire
Patient’s CPR-number: ________________     Name:   __________________________ 
A. Mark tumor localization: Number the tumors: 1-?
B. Treatment date: ________________
C. Is a part of the tumor < 5 mm from the orifices
Tumor number
1 2 3 4 5
If yes, specify tumor number
D. Clinical evaluation of tumor type
Tumor number
1 2 3 4 5
Basal cell carcinoma of nodular type
Basal cell carcinoma of superficial type
Basal cell carcinoma of morphea type
Squamous cell carcinoma
Mb. Bowen
Keratoacanthoma
Other type, specify: _____________________
E. Is/are the tumor(s) recurrent cancer?
Tumor number
1 2 3 4 5
No 
If yes, note year of primary cancer Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
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F. Tumor size in diameter (mm)
Tumor number
1 2 3 4 5
Size in mm mm mm mm mm mm
G. Clinical tumor thickness
Tumor number
1 2 3 4 5
,2 mm
$2 mm
H. Information on metastasis
Regional metastasis No regional lymphnode metastases
  Regional lymphnode metastases
Distant metastases No distant node metastases
Distant node metastases
I.Treatments
Tumor number
1 2 3 4 5
Cryotherapy
Curettage
Curettage and cautery/electrodesiccation (one cycle)
Curettage and cautery/electrodesiccation (two cycles)
Excision (4 mm margin)
Excision (6 mm margin)
Photodynamic therapy
Radiotherapy
5-fluouracil
Imiquimod creme
Other treatment, specify: ______________________
Refered to hospital 
department
Plastic surgery
Oncology
Other: __________________
Decided no treatment
Patient does not want any treatment
J. Patient’s skin?
  Skin type 1 (very light, always sunburnt, never tans)
  Skin type 2 (light, easily sunburns, rarely tans)
  Skin type 3 (rarely sunburnt, easily tans)
  Skin type 4 (slightly dark glow, never sunburnt, always tan)
  Skin type 5 (Congenital dark skin, never sunburnt)
  Skin type 6 (Congenital very dark, never sunburnt) Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
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Skin cancer history
K. Has the patient been diagnosed with skin cancer previously?
 Yes                        No                        Unknown
If yes, specify (one or more X):
  Basal cell carcinoma
  Squamous cell carcinoma
  Malignant melanoma
  unknown tumor type
  Other kind, specify: ________________
If yes, has the patient been diagnosed with skin cancer more than once before?
 Yes                        No
If yes, how many times:
  ,5 times
  5 til 20 times
  .20 times
L. Histological evaluation
Tumor number
1 2 3 4 5
Basal cell carcinoma
Squamous cell carcinomad
Mb. Bowen
Keratoakanthom
Other type, specify: _____________________
Histological examination has not been made
M. Diagnosis:
Macroscopic
  Surgery
  Clinical examination
Microscopic
  Histology from primary tumour
  Histology from metastasis
    Histology from primary tumour/metastasis 
unspecified
  Others Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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Appendix 2: Follow up visit questionnaire
Patient’s CPR-number: ________________ Name:   __________________________
A. Date of follow up visit: ________________
B. Are there signs of residual tumor or tumor recurrence in the treated area:          yes    No
If yes, 
Which tumor(s) still show signs of activity 
Specify the kind of activity
Tumor number
1 2 3 4 5
Residual tumor
Tumor recurrence
C. Have you had a new histologic examination performed this time?                     yes    No
If yes,
Specify the kind of cancer found
Tumor number
1 2 3 4 5
Basal cell carcinoma
Squamous cell carcinoma
Mb bowen
Keratoakanthoma
Other kind, specify _____________________
D. In your opinion, how good is the cosmetic result? 
  very satisfactory
  satisfactory
  acceptable
  bad
E. Patients opinion on the cosmetic result on a scale from 1 to 10:
  (1= worst possible and 10 = best possible?) 
  Enter patients rating here: _____________________
H.  Has there been any complications to the treatment                  yes    No
Type of complication
Tumor nummer
1 2 3 4 5
Pain
    On the treatment day
  ≤7 days after treatment
  .7 days after treatment
  Wound infection
  Bleedings
  Retarded wound heeling >1 month
  EdemaClinical Epidemiology
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Appendix 3
SNOMED typography: T021, T022, T023, T024, T025, T026, T027, T028, T01000, T01520
SNOMED Morphology
Basal cell: M80902, M80903, M80904, M80906, M80907, M80913, M80923, M80924, M80926, M80927, M80933, 
M80934, M80936, M80937, M80943, M80944, M80946, M80947, M80953, M80954, M80956, M80957
Squamous cell: M80513, M80514, M80515, M80516, M80517, M80518, M80519, M80703, M80704, M80706, M80707, 
M80708, M80709, M80713, M80714, M80716, M80717, M80718, M80719, M80743, M80744, M80746, M80747, 
M80748, M80749, M80753, M80754, M80756, M80757, M80758, M80759, M80763, M80783, M80784, M80786, 
M80787, M80788, M80789
Mb. Bowen: M80812, M80702
Kerathoacanthoma: M72860